LMR Partners’s Heron Therapeutics HRTX Stock Holding History

LMR Partners’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-13,363	Closed	-$326K	–	291
2015 Q3	$326K	Buy	+13,363	New	+$445K	0.04%	252
2015 Q2	–	Sell	-10,113	Closed	-$147K	–	565
2015 Q1	$147K	Buy	+10,113	New	+$114K	0.02%	366
2014 Q2	–	Sell	-14,367	Closed	-$200K	–	497
2014 Q1	$200K	Buy	+14,367	New	+$192K	0.03%	224

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LMR Partners's HRTX Position: Q4 2015 in Review

LMR Partners sold out of Heron Therapeutics (HRTX) in Q4 2015, closing a stake of 13,363 shares — an estimated $326K sold.

LMR Partners first reported a position in HRTX in Q1 2014 and held it in 3 quarters. The position peaked at $326K in Q3 2015. 107 funds tracked by Wall St. Rank hold HRTX as of Q4 2015.

LMR Partners reported no remaining Heron Therapeutics position as of Q4 2015 after selling out during the quarter.
LMR Partners sold 13,363 Heron Therapeutics shares in Q4 2015, an estimated $326K.
LMR Partners first reported a position in Heron Therapeutics in Q1 2014 and held it in 3 quarters.
LMR Partners's Heron Therapeutics position peaked at $326K in Q3 2015.
107 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2015.

Based on LMR Partners's 13F filing for Q4 2015, filed 3 Feb 2016.